Renal Cell Carcinoma
Specialty Channel

Featured Article
Which study reported OS results in favor of axitinib plus pembrolizumab, ultimately obtaining the lowest hazard ratio observed for survival in any phase 3 trial, a benefit seen across prognostic risk…
The FDA has approved tivozanib for the treatment of certain pre-treated patients with relapsed/refractory advanced RCC.
Pembrolizumab monotherapy as a first-line treatment showed promising antitumor activity in treatment-naive ccRCC patients.
Axitinib showed a better tumor response rate than nivolumab, according to a study comparing the 2 as second-line treatment in mRCC.
Which combo therapy regimen was approved by the FDA for the treatment of advanced RCC in January 2021?
The FDA has approved nivolumab plus cabozantinib for patients with advanced renal cell carcinoma.
A study including the largest metastatic RCC cohort to date has shown that ctDNA testing is viable and efficient for detecting genomic alterations in this patient population.
In the largest real-world study to date, researchers found cabozantinib effective in treating heavily pretreated patients with metastatic RCC.
Findings from a cohort study show ICI rechallenge yields reasonable safety and efficacy in patients with metastatic RCC.

News

The FDA has approved tivozanib for the treatment of certain pre-treated patients with relapsed/refractory advanced RCC.
Pembrolizumab monotherapy as a first-line treatment showed promising antitumor activity in treatment-naive ccRCC patients.
Axitinib showed a better tumor response rate than nivolumab, according to a study comparing the 2 as second-line treatment in mRCC.
The FDA has approved nivolumab plus cabozantinib for patients with advanced renal cell carcinoma.

Interactive Features

Which study reported OS results in favor of axitinib plus pembrolizumab, ultimately obtaining the lowest hazard ratio observed for survival in any phase 3 trial, a benefit seen across prognostic risk…
Which combo therapy regimen was approved by the FDA for the treatment of advanced RCC in January 2021?
Which therapy had a better safety profile and OS rate in the SAVOIR trial for papillary RCC?
True or False: Pembrolizumab combined with bevacizumab was proven safe and active in a study of patients with metastatic clear cell renal cell carcinoma.
Stay in the know.
OncNet Newsletter